Related Experiment Video
Updated: Apr 24, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Larger baseline body stature predicts one-year amyloid change in cognitively normal older adults enriched with
Aaron N Smith1, Jeffrey M Burns2,3, Debra K Sullivan1,3,4,5
1Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS, USA.
Abstract:
BackgroundRising Alzheimer's disease (AD) incidence underscores the need to identify modifiable risk factors. The "obesity paradox" suggests higher late-life body mass index (BMI) may reduce AD risk. Because BMI does not distinguish between fat and lean mass, investigating body composition and brain amyloid accumulation may clarify this relationship.ObjectiveThis study tested whether baseline body stature predicts one-year change in brain amyloid.MethodsUsing data from the Alzheimer's Prevention through Exercise trial, we examined whether baseline body stature and composition (BMI, fat mass index [FMI], lean mass index [LMI], and total fat and lean mass) predicted one-year change in brain amyloid among 106 cognitively healthy older adults enriched with elevated amyloid status.ResultsHigher baseline BMI predicted less one-year amyloid accumulation globally (β = -0.33, p = 0.001) and in five of six brain regions (p = 0.001-0.05). Higher FMI predicted less amyloid accumulation globally (β = -0.35, p < 0.001) and in all six regions (p < 0.001-0.02), while higher LMI predicted less accumulation globally and in four regions (p < 0.001-0.02). Higher total fat mass was associated with less amyloid globally and regionally (p < 0.001-0.02), whereas higher total lean mass predicted reduced accumulation only in the lateral temporal lobe (p = 0.01).ConclusionsLarger body mass predicted less amyloid accumulation in cognitively healthy older adults over one year. More research is needed to investigate whether larger body stature protects against amyloid accumulation and explore underlying mechanisms.Clinical Trial RegistrationClinicalTrials.gov, Identifier (NCT02000583).
More Related Videos
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
Related Concept Videos
Alzheimer Disease l: Introduction
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Cognitive Development During Adulthood
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils